Altimmune (NASDAQ: ALT – Get a rating) saw its price target lowered by Guggenheim equity researchers to $27.00 in a research report released on Monday, Target Stock Advisor reports. The company currently has a “na” rating on the stock. Guggenheim’s price target suggests a potential upside of 461.33% from the current stock price.
ALT has been the subject of several other reports. Zacks Investment Research upgraded Altimmune from a “sell” rating to a “hold” rating in a Wednesday, March 16 report. B. Riley reduced his price target on Altimmune from $27.00 to $21.00 in a Monday, January 24 report. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on Altimmune shares in a Tuesday, March 22 research report. One research analyst has rated the stock with a hold rating and six have assigned the stock a buy rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $25.16.
Stock Altimmune traded down $0.35 in midday trading on Monday, hitting $4.81. The company’s stock had a trading volume of 733,521 shares, compared to an average volume of 804,857. Altimmune has a 12-month low of $3.83 and a 12-month high of $19.46. The company has a market capitalization of $207.90 million, a PE ratio of -1.99 and a beta of 1.45. The stock’s 50-day moving average price is $5.66 and its 200-day moving average price is $7.72.
Altimmune (NASDAQ: ALT – Get a rating) last reported results on Thursday, May 12. The company reported ($0.44) EPS for the quarter, beating analyst consensus estimates of ($0.57) by $0.13. Altimmune had a negative net margin of 2,819.11% and a negative return on equity of 41.69%. During the same period of the previous year, the company posted an EPS of ($0.38). As a group, equity analysts predict Altimmune will post -2.37 EPS for the current fiscal year.
In related news, insider Matthew Scott Harris sold 30,000 shares of the company in a transaction on Monday, February 28. The stock was sold at an average price of $7.52, for a total transaction of $225,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. Insiders own 3.14% of the shares of the company.
Several institutional investors and hedge funds have recently increased or reduced their stake in ALT. Royal Bank of Canada increased its position in Altimmune shares by 2,032.1% during the second quarter. Royal Bank of Canada now owns 3,987 shares of the company worth $39,000 after acquiring 3,800 more shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in Altimmune in the fourth quarter worth approximately $49,000. Graham Capital Management LP purchased a new stake in Altimmune during Q1 worth approximately $63,000. Engineers Gate Manager LP acquired a new position in Altimmune during Q1 worth approximately $87,000. Finally, BNP Paribas Arbitrage SA increased its stake in Altimmune shares by 172.7% in the third quarter. BNP Paribas Arbitrage SA now owns 9,330 shares in the company valued at $106,000 after purchasing an additional 5,909 shares in the last quarter. 88.00% of the shares are currently held by institutional investors and hedge funds.
Altimmune Company Profile (Get a rating)
Altimmune, Inc., a clinical-stage biopharmaceutical company, is focused on developing treatments for obesity and liver disease. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a dual GLP-1/glucagon receptor agonist that is in Phase 1b testing for the treatment of obesity and non-alcoholic steatohepatitis.
Get news and reviews for Altimmune Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst assessments for Altimmune and related companies with MarketBeat.com’s free daily email newsletter.